Piper Sandler Lowers Gossamer Bio (NASDAQ:GOSS) Price Target to $15.00

Gossamer Bio (NASDAQ:GOSSGet Rating) had its target price reduced by equities research analysts at Piper Sandler from $26.00 to $15.00 in a research note issued on Monday, The Fly reports. Piper Sandler’s price objective would suggest a potential upside of 81.60% from the stock’s current price.

Other equities research analysts have also issued research reports about the stock. Citigroup upgraded shares of Gossamer Bio from a “neutral” rating to an “outperform” rating and set a $24.00 price target for the company in a report on Monday, January 10th. Sumitomo Mitsui Financial Group upgraded shares of Gossamer Bio from a “neutral” rating to an “outperform” rating and set a $24.00 price objective on the stock in a research note on Monday, January 10th. Zacks Investment Research upgraded shares of Gossamer Bio from a “sell” rating to a “hold” rating in a research report on Tuesday, March 8th. Raymond James began coverage on shares of Gossamer Bio in a research note on Monday, April 18th. They issued an “outperform” rating and a $19.00 price target on the stock. Finally, UBS Group started coverage on shares of Gossamer Bio in a research note on Wednesday, April 6th. They set a “buy” rating and a $19.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $20.00.

Shares of NASDAQ:GOSS traded down $0.54 during trading on Monday, reaching $8.26. 180,386 shares of the stock traded hands, compared to its average volume of 634,118. Gossamer Bio has a 52-week low of $7.04 and a 52-week high of $14.30. The company has a debt-to-equity ratio of 1.47, a quick ratio of 8.32 and a current ratio of 8.32. The stock has a 50-day moving average of $9.08 and a two-hundred day moving average of $10.52. The stock has a market cap of $631.70 million, a P/E ratio of -2.65 and a beta of 1.03.

Gossamer Bio (NASDAQ:GOSSGet Rating) last announced its quarterly earnings data on Thursday, March 3rd. The company reported ($0.74) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.74). During the same quarter in the prior year, the company earned ($0.88) EPS. Sell-side analysts expect that Gossamer Bio will post -3.09 earnings per share for the current year.

In other Gossamer Bio news, EVP Waage Christian sold 10,722 shares of the company’s stock in a transaction on Wednesday, March 23rd. The stock was sold at an average price of $8.91, for a total value of $95,533.02. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Laura Carter sold 5,002 shares of the business’s stock in a transaction on Wednesday, March 16th. The stock was sold at an average price of $8.28, for a total value of $41,416.56. The disclosure for this sale can be found here. In the last ninety days, insiders sold 41,038 shares of company stock valued at $358,542. 23.30% of the stock is currently owned by corporate insiders.

Several institutional investors have recently made changes to their positions in the business. FMR LLC bought a new position in Gossamer Bio in the first quarter valued at approximately $26,576,000. Invesco Ltd. increased its stake in shares of Gossamer Bio by 26.1% in the 2nd quarter. Invesco Ltd. now owns 49,081 shares of the company’s stock valued at $398,000 after purchasing an additional 10,145 shares during the last quarter. SG Americas Securities LLC bought a new stake in Gossamer Bio during the 3rd quarter worth $614,000. Close Asset Management Ltd acquired a new position in Gossamer Bio during the 3rd quarter worth about $72,000. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Gossamer Bio by 11.8% in the 3rd quarter. Goldman Sachs Group Inc. now owns 571,917 shares of the company’s stock valued at $7,189,000 after purchasing an additional 60,342 shares during the period. Institutional investors own 71.59% of the company’s stock.

About Gossamer Bio (Get Rating)

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis.

See Also

The Fly logo

Analyst Recommendations for Gossamer Bio (NASDAQ:GOSS)

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.